Oral Bisphosphonate Use and All-Cause Mortality in Patients With Moderate–Severe (Grade 3B-5D) Chronic Kidney Disease: A Population-Based Cohort Study
Open Access
- 22 January 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 35 (5) , 894-900
Abstract
Oral Bisphosphonates (oBP) have been associated with reduced fractures and mortality. However, their risks and benefits are unclear in patients with moderate‐severe CKD. This study examined the association between oBP and all‐cause mortality in G3B‐5D CKD. This is a population‐based cohort study including all subjects with an eGFR2 aged 40+ years from the UK Clinical Practice Research Datalink (CPRD) and the Catalan Information System for Research in Primary Care (SIDIAP). Previous and current users of other anti‐osteoporosis drugs were excluded. oBP use was modelled as a time‐varying exposure to avoid immortal time bias. Treatment episodes in oBP users were created by concatenating prescriptions until patients switched or stopped therapy or were censored or died. A washout period of 180 days was added to (date of last prescription +180 days). Propensity scores (PS) were calculated using pre‐specified predictors of mortality including age, gender, baseline eGFR, socio‐economic status, co‐morbidities, previous fracture, co‐medications and number of hospital admissions in the previous year. Cox models were used for PS adjustment before and after PS trimming (the first and last quintiles). In the CPRD, of 19,351 oBP users and 210,954 non‐oBP users, 5,234 (27%) and 85,105 (40%) deaths were recorded over 45,690 and 915,867 person‐years of follow‐up, respectively. oBP users had 8% lower mortality risk compared to non‐oBP users (HR 0.92, 95% CI 0.89‐0.95). Following PS trimming, this became non‐significant (HR 0.98, 95% CI 0.94‐1.04). In the SIDIAP, of 4,146 oBP users 86,127 non‐oBP users, 1,330 (32%) and 36,513 (42%) died, respectively. oBP were not associated with mortality in PS adjustment and trimming (HR 1.04, 95% CI 0.99‐1.1 and HR 0.95, 95% CI 0.89‐1.01). In this observational, patient‐based cohort study, oBP were not associated with increased mortality amongst patients with moderate‐severe CKD. However, further studies are needed on other effects of oBP in CKD patients.Keywords
Funding Information
- National Health and Medical Research Council (1008219, 1073430, 1114676)
- National Institute for Health Research (CS-2013-13-012)
- Biomedical Research Centre
- National Health and Medical Research Council (1008219, 1073430, 1114676)
- National Institute for Health Research (CS‐2013‐13‐012)
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
This publication has 43 references indexed in Scilit:
- The risk of upper gastrointestinal bleeding in patients treated with hemodialysis: a population-based cohort studyBMC Nephrology, 2013
- A single-dose study of denosumab in patients with various degrees of renal impairmentJournal of Bone and Mineral Research, 2012
- Effects of denosumab on fracture and bone mineral density by level of kidney functionJournal of Bone and Mineral Research, 2011
- Treatment Effects in the Presence of Unmeasured Confounding: Dealing With Observations in the Tails of the Propensity Score Distribution--A Simulation StudyAmerican Journal of Epidemiology, 2010
- Effect of Osteoporosis Treatment on Mortality: A Meta-AnalysisThe Journal of Clinical Endocrinology & Metabolism, 2010
- Validation and validity of diagnoses in the General Practice Research Database: a systematic reviewBritish Journal of Clinical Pharmacology, 2009
- Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal womenKidney International, 2008
- Zoledronic Acid and Clinical Fractures and Mortality after Hip FractureNew England Journal of Medicine, 2007
- Risk of Subsequent Fracture After Low-Trauma Fracture in Men and WomenJAMA, 2007
- Safety and Efficacy of Risedronate in Patients With Age-Related Reduced Renal Function as Estimated by the Cockcroft and Gault Method: A Pooled Analysis of Nine Clinical TrialsJournal of Bone and Mineral Research, 2005